Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0025202 (melanoma)
 69,561 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Membrane antigens of a cultured human melanoma line, UCLASO-M14, were studied using immune adherence techniques. Allogeneic sera from melanoma patients that were reactive with the M14 but nonreactive with lymphoid cells of the M14 donor were used as antibodies. The antigen responsible for the reaction between M14 and the antibodies was searched for in other cancer, normal, and fetal tissues using antibody absorption techniques. The antigen was found in a variety of different histological types of biopsied and cultured cancer cells as well as in melanomas. The antigen did not exist in biopsied normal tissues, but it appeared in cultured normal skin and muscle. Neither normal lymphocytes nor cultured lymphoid cells showed any antigenicity. The antigen was present in human fetal tissues and was the strongest in fetal brain tissues at 22 weeks of development. Liver, spleen, thymus, and small intestine from the same fetus were negative for antigen.
Cancer Res 1976 Sep
PMID:A membrane antigen common to human cancer and fetal brain tissues. 6 13

Antibody-dependent cell-mediated cytotoxic assays have been used to examine antigens on human melanoma cells obtained either directly from patients or from long-term melanoma cell lines. A panel of melanoma antisera was selected from human subjects which could be shown not to have significant reactivity to histocompatibility antigens. With these antisera extensive cross-reactions between melanoma cells were found. However, the cross-reactivity was incomplete and the pattern of reactivity was different for each antiserum tested. These results were not consistent with a common melanoma antigen on human melanoma cells but rather indicated heterogeneity of melanoma antigens and multiple antibody specificities in the sera tested. This appeared to be confirmed by extensive cross-absorption studies which indicated limited cross-reactivity of antigens on melanoma cells from either long-term or short-term cultures. Several changes in the antigenic profile of melanoma cells in vitro from both long-term and short-term cultures were documented which resulted from contamination of the melanoma cell lines with non-melanoma cells and fibroblasts. Melanoma antisera may therefore be useful to mintor changes in long-term cultures which would otherwise give spurious results in in vitro tests. These results appear to have considerable significance for understanding tumour/host relationships and for the establishment of rational immunotherapeutic procedures and diagnostic tests in melanoma.
Int J Cancer 1976 Nov 15
PMID:Antigens on melanoma cells detected by leukocyte dependent antibody assays of human melanoma antisera. 6 19

The paper reports on 11 patients with very advanced melanoma, who were treated with a modified version of multiple-stage cancer therapy. No improvement in the course of the illness resulted, but survival may have been slightly prolonged.
 ...
PMID:[Multiple-stage treatment of malignant melanoma (author's transl)]. 6 97

The authors modified and refined the Leukocyte Adherence Inhibition Assay (LAI) first described by Halliday, et al. in 1972 by standardizing the protein concentration of tumor-associated antigens (TAA) and by utilizing paired normal tissue extracts as controls to eliminate interference of HL-A histocompatibility antigens and organ-associated antigens. When dose response studies were performed, a progressively larger percentage of patients reacted to the LAI test with increasing concentration of tumor extracts, but the optimal concentration was found to be 200 mug/ml, where 42 out of 66 (63%) leukocytes from 54 breast cancer patients reacted to the breast cancer extracts. At this dose range, only three out of 39 (7%) normal donors and four out of 30 (13%) patients with other types of cancer were positive. When breast cancer patients were tested against TAA of colon cancer and malignant melanoma, one of 24 (4%) and two of 24 (8%), respectively, were positive. Although a higher response rate (72%) was noted in Stage II disease, this was not statistically different from Stage I and Stage III disease. Likewise, no difference was noted in LAI at varying phases following the mastectomy.
Cancer 1977 Feb
PMID:Leukocyte adherence inhibition by soluble tumor antigens in breast cancer patients. 6 7

Seventeen patients with disseminated malignant melanoma were treated with DTIC (150 mg/m2, Days 1-5) and cyclocytidine (increasing doses sc, Days 1-10) in a phase I-II study. There was one early death. The remaining 16 patients were evaluable for response and toxicity. Two patients (13%) had CR lasting 8+ and 2+ months, while one patient (6%) had a PR lasting 1 month. Nausea and vomiting was seen in seven patients (44%), jaw pain in four (25%), and orthostatic hypotension in two (13%). Hematologic toxicity was not excessive, nor was it cumulative. The overall response rate of 19% was comparable to that reported with DTIC alone. This drug combination does not appear to offer any therapeutic advantage within the dosage range tested in disseminated malignant melanoma.
Cancer Treat Rep 1976 Sep
PMID:Phase 1-11 study of DTIC and cyclocytidine in disseminated malignant melanoma. 6 23

By means of the complement-dependent microcytotoxicity test, cytotoxic antibodies to melanoma cells in long-term culture were detected in 34 of 90 sera from melanoma patients. The incidence of cytotoxic antibodies in melanoma patients was significantly greater than in subjects free of malignant disease but not significantly greater than in patients with other types of cancer. The sera were cytolytic to melanoma cells only in conjunction with rabbit complement, and they reacted with the pabel of melanoma cells in a distinct fashion. No association was found between presence of cytotoxic antibodies and the occurrence of metastasis.
J Natl Cancer Inst 1977 May
PMID:Cytotoxic antibodies to cultured melanoma cells in the sera of melanoma patients. 6 8

There are many quantitative changes of serum protein and immunoglobulin fractions in patients with cancer of various sites, excluding those with leukemic and lymphoproliferative disorders. The commonest change in serum proteins of patients with neoplastic disease is a reduction in albumin concentration and elevation of alpha globulins, especially alpha-2 fraction. Immunoglobulins (IgG, A,M) are a heterogenous group of proteins contained in the gamma, beta, and alpha-2 electrophoretic fractions of serum proteins. The IgG was found to be significantly increased in patients with cancer of the skin and lung, but decreased in patients with cancer of the prostate and breast. Serum IgM was reported to be elevated in patients with sarcoma, melanoma, brain tumors, but decreased in patients with carcinoma of the ovary. Serum IgA was found to be elevated in patients with cancer of epithelial secretory organs, such as skin, breast, head and neck, lung, gut, prostate, and uterine cervix. Whether these findings reflect specific changes of the humoral arm of tumor-host interaction remains to be investigated.
 ...
PMID:Quantitative change of serum protein and immunoglobulin in patients with solid cancers. 6 75

A phase I-II study of cyclocytidine was conducted in 102 patients, 96 of whom had metastatic solid tumors and six of whom had acute leukemia. The drug was administered in 5- or 10-day courses of single daily iv or sc injections of 100-675 mg/m2 day. Two complete and six partial responses were observed in 64 solid tumor patients evaluable for response, 52 of whom had malignant melanoma or adenocarcinoma of gastrointestinal origin. The median duration of the responses was 6 months. An additional seven patients achieved stabilization of their disease for greater than or equal to 2 months. No responses occurred in six patients with acute leukemia. Side effects included nausea and vomiting, postural hypotension, and parotid pain, occurring in approximatley one third of patients receiving greater than 200 mg/m2/day. No myelosuppression was observed in six patients receiving 5-day courses of 100-200 mg/m2/day. Myelosuppressive toxicity became increasingly severe with doses greater than 200 mg/m2/day x 10, related at least in part to prior chemotherapy exposure including the nitrosoureas.
Cancer Treat Rep
PMID:Phase I-II evaluation of cyclocytidine. 6 28

The expression of HLA antigens and beta2-microglobulin (beta2-mu) on cultured melanoma cells originated from 11 patients has been quantitated and compared with that on fibroblasts and cultured human lymphoid cells originated from the same patients. No qualitative or quantitative difference was detected with the exception of one melanoma line. HLA antigens were also quantitated in sera from melanoma patients: two sera reacted with anti-HLA-B7 antibodies although this specificity was not expressed on lymphocytes from whom the sera were obtained. A technique to quantitate HLA antigens on cells developed in the course of this study is described.
Cancer 1977 Jul
PMID:Expression of histocompatibility (HLA) antigens on tumor cells and normal cells from patients with melanoma. 6 83

To identify soluble cell surface melanoma-associated antigens (MAA), human melanoma cells in culture were radioiodinated by the lactoperoxidase technique and solubilized in non-ionic detergent (NP-40). Labelled MAA were identified by a quantitative double-antibody antigen binding assay and unrelated labelled macromolecules by trichloroacetic acid precipitation. Detergent solubilized 95% of the macromolecule-associated radioactivity. Approximately 8%, presumably MAA, was bound specifically by anti-melanoma serum. In contrast, anti-melanoma serum bound specifically only 0.5 to 1.5% of the acid precipitable radioactivity in control cells iodinated in a similar manner. Specificity was further studied by quantitative serum absorption. Two different melanoma lines were equally effective in inhibiting specific binding of iodinated melanoma lysate, whereas 50-100 times more normal fresh lymphocytes, liver and spleen cells, cultured HeLa or colon adenocarcinoma cells, and 8 times more cultured fetal cells were required to produce similar reductions in specific binding. These studies demonstrate that cell surface human melanoma antigens that differ qualitatively and/or quantitatively from those on normal or malignant allogeneic tissues can be solubilized and identified. These antigens are shared with other melanomas, and some are also present on fetal cells.
Int J Cancer 1977 Aug 15
PMID:Identification and solubilization of iodinated cell surface human melanoma associated antigens. 7 Apr 12


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>